Clinical trials: Cancer of the Prostate
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Prostate Cancer
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
- Trial name
- NCT02213107
- Testing
- Enzalutamide and Dutasteride or finasteride
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Rochester
Prostate Cancer
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
The purpose of this study is to test different methods for communicating information about prostate cancer treatment to men. The investigators are studying how best to present information so men can make informed decisions about…
- Trial name
- NCT00432601
- Testing
- type of decision aid
- Where
- 4 sites in United States
- Volunteers
- 1,028 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer.
- Trial name
- NCT01667536
- Testing
- Drug: 99mTc-MIP-1404
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostatic Neoplasms
Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
The purpose of the study is to evaluate the usefulness of 3-T magnetic resonance imaging (MRI) in the evaluation of suspected prostate cancer.
- Trial name
- NCT01357512
- Testing
- magnetic resonance imaging, Siemens
- Where
- Finland
- Volunteers
- 130 people
- Sponsor
- University of Oulu
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Background: Some prostate cancer keeps growing even when testosterone in the body drops to very low levels. This is called castrate-resistant prostate cancer. One treatment is enzalutamide. This is a modern hormonal therapy.
- Trial name
- NCT03531827
- Testing
- enzalutamide, CRLX101
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone metastases and no known visceral metastatic disease.
- Trial name
- EXCAAPE (NCT03002220)
- Testing
- radium-223
- Where
- 6 sites in Spain
- Volunteers
- 52 people
- Sponsor
- MedSIR
Hormone Treatment-naïve Participants With Prostate Cancer
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.
- Trial name
- NCT02141659
- Testing
- TAK-385
- Where
- 6 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Takeda
Prostate Cancer
DeADT - Living Well With Prostate Cancer
The goal of this randomized de-implementation trial is to compare two strategies to reduce low-value androgen deprivation therapy (ADT) use for prostate cancer care.
- Trial name
- DeADT-LW (NCT06199986)
- Testing
- ADT Order Check Attestation (Or), Provider Script (Sc)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Prostate Cancer
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of…
- Trial name
- NCT01485861
- Testing
- Abiraterone, Apitolisib, Ipatasertib
- Where
- 59 sites in United States, Czechia and 7 more
- Volunteers
- 298 people
- Sponsor
- Genentech, Inc.
Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.
- Trial name
- NCT02116582
- Testing
- Enzalutamide
- Where
- 50 sites in Belgium, France and 3 more
- Volunteers
- 215 people
- Sponsor
- Astellas Pharma Europe B.V.
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This phase II trial is studying how well giving gossypol together with androgen ablation therapy works in treating patients with newly diagnosed metastatic prostate cancer.
- Trial name
- NCT00666666
- Testing
- AT-101, Bicalutamide, LHRH agent
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance.
- Trial name
- NCT00630344
- Testing
- RAD001, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
The study is to examine a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer.
- Trial name
- NCT02874014
- Testing
- Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Prostate Cancer Metastatic
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of…
- Trial name
- PROfind (NCT03490032)
- Testing
- [68Ga]-PSMA-R2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Advanced Accelerator Applications
Covid19, Genito Urinary Cancer
Description of the Population With Genitourinary Tumors and COVID-19
The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health…
- Trial name
- SOGUGCOVID (NCT04578132)
- Where
- 32 sites in Spain
- Volunteers
- 410 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
The purpose of the study is to find out whether imaging of the prostate with a new molecule called 68Ga-PSMA can find prostate cancer.
- Trial name
- NCT03689582
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in…
- Trial name
- PRESERVE (NCT04972097)
- Testing
- Irreversible Electroporation
- Where
- 17 sites in United States
- Volunteers
- 121 people
- Sponsor
- Angiodynamics, Inc.
Prostate Cancer
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
- Trial name
- NCT00466440
- Testing
- enzastaurin, docetaxel, prednisone
- Where
- 28 sites in United States, Germany and 1 more
- Volunteers
- 108 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
VMAT for Dominant Intraprostatic Lesion
The aim of this study was to determine the efficacy and safety of the implementation of a program of " image-guided focal Intensification dose to intraprostatic dominant lesion " in men with localized prostate cancer (PCa) of…
- Trial name
- CaP-VMAT-DIL (NCT03030625)
- Testing
- IGRT/VMAT focal therapy boost to DIL
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.